U.S. Liquid Biopsy Market Size, Share, and Growth Forecast, 2026 – 2033

The U.S. liquid biopsy market size is likely to be valued at US$2.1 billion in 2026 and is expected to reach US$5.1 billion by 2033, growing at a CAGR of 13.6% during the forecast period from 2026 to 2033, driven by the rising prevalence of cancer, increasing adoption of non-invasive diagnostic technologies, and the growing focus on precision oncology and personalized treatment strategies. The rising cancer burden in the U.S. and the increasing focus on early detection are accelerating the adoption of advanced diagnostic approaches in clinical practice. In the U.S. alone, more than 2 million new cancer cases are diagnosed each year, underscoring the importance of innovative diagnostic technologies that can support timely clinical decision-making. Globally, WHO projects that the cancer burden will continue to rise significantly, with more than 35 million new cases expected annually by 2050, reflecting increasing population aging, lifestyle risk factors, and improved detection rates. Increasing focus on precision medicine and personalized oncology therapies is driving demand for molecular profiling tools that can guide targeted treatment decisions. Regulatory support and expanding clinical validation studies are strengthening the integration of liquid biopsy tests into routine oncology workflows.

• Leading Product Type: Kits & reagents are projected to represent the leading product type in 2026, accounting for 55% of the revenue share, driven by their extensive use in liquid biopsy sample preparation and routine biomarker extraction workflows.
• Leading Biomarker Type: Circulating tumor DNA (ctDNA) is anticipated to be the leading biomarker type, accounting for over 42% of the revenue share in 2026, supported by its high accuracy in detecting tumor-specific genetic mutations and guiding targeted cancer therapies.
• Leading Indication Type: Lung cancer is estimated to represent the leading indication type in 2026, accounting for 22% of the revenue share, driven by the widespread use of liquid biopsy tests for mutation profiling and targeted therapy selection.

Growth Analysis- Increasing Prevalence of Cancer and Demand for Early Detection

Cancer incidence continues to rise due to aging populations, lifestyle changes, and environmental risk factors. Healthcare systems are focusing more on early detection and timely diagnosis. Liquid biopsy provides a minimally invasive method to detect tumor-derived biomarkers in blood, allowing clinicians to identify cancers earlier compared with conventional tissue biopsies. This capability is particularly valuable in cancers where repeated tissue sampling is difficult or risky. As awareness of early cancer screening grows, physicians and diagnostic laboratories are increasingly incorporating liquid biopsy tests into clinical workflows. The increasing adoption of circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) analysis in routine testing drives market demand, while FDA-cleared kits such as Guardant360 and QIAamp support standardization in clinical practice.

The growing emphasis on precision oncology has strengthened the demand for advanced diagnostic tools capable of providing real-time molecular insights. Liquid biopsy enables continuous monitoring of tumor mutations, treatment response, and disease progression without the need for surgical procedures. This approach supports earlier therapeutic intervention and helps clinicians select targeted therapies tailored to a patient’s genetic profile. Hospitals, research institutions, and diagnostic laboratories are increasingly investing in liquid biopsy platforms to enhance oncology care. As healthcare providers prioritize early detection and personalized treatment strategies, the rising cancer burden continues to accelerate the growth and adoption of liquid biopsy technologies.

Advancements in Genomic Sequencing Technologies

Innovations in next-generation sequencing and digital polymerase chain reaction platforms have improved the sensitivity, accuracy, and speed of detecting tumor-derived genetic material in blood samples. These technologies enable clinicians to analyze circulating tumor DNA and other molecular biomarkers with greater precision. Liquid biopsy tests can identify genetic mutations, track tumor evolution, and guide targeted therapies more effectively than earlier diagnostic methods. Continuous technological improvements are expanding the capabilities of liquid biopsy in clinical oncology. The development of multi-gene panels and ultra-sensitive assays is enhancing the detection of minimal residual disease (MRD), increasing the adoption of liquid biopsy in monitoring high-risk cancer patients and supporting precision treatment decisions.

The integration of advanced bioinformatics tools with sequencing platforms has enhanced the interpretation of complex genomic data generated from liquid biopsy tests. Automated analytical systems allow researchers and clinicians to detect rare mutations and monitor molecular changes during treatment. Pharmaceutical companies also use these technologies to support biomarker-driven drug development and companion diagnostics. As sequencing technologies become more efficient and accessible, the clinical adoption of liquid biopsy continues to increase across hospitals, diagnostic laboratories, and research centers.

Barrier Analysis - Lack of Standardization across Assays

One of the key challenges in the liquid biopsy market is the lack of standardized testing protocols and assay methods across laboratories and diagnostic platforms. Different liquid biopsy tests often use varying sample collection procedures, biomarker targets, sequencing technologies, and data interpretation methods. This variation can lead to inconsistencies in test results, making it difficult for healthcare providers to compare findings across different diagnostic providers. Inconsistent methodologies also complicate regulatory evaluation and clinical validation, slowing the widespread adoption of liquid biopsy technologies in routine oncology practice.

The absence of universally accepted standards also creates barriers for clinicians seeking reliable diagnostic information for treatment decision-making. Without standardized assay procedures, it becomes challenging to establish uniform clinical guidelines for liquid biopsy applications such as cancer screening, treatment monitoring, and recurrence detection. Regulatory agencies and industry organizations are working to develop standardized frameworks for biomarker testing and validation. Until consistent methodologies are widely implemented, concerns regarding test reliability and reproducibility limit the broader integration of liquid biopsy technologies into mainstream clinical diagnostics.

Limited Sensitivity for Early-Stage Detection

In early-stage tumors, the concentration of circulating tumor DNA and other biomarkers in the bloodstream is often extremely low. This low biomarker presence can make detection challenging, even with advanced sequencing technologies. Some early-stage cancers remain undetected or produce inconclusive test results. These sensitivity limitations reduce the reliability of liquid biopsy as a standalone screening tool for certain cancer types and require confirmation through conventional tissue biopsy methods. This limitation is particularly significant in cancers such as pancreatic and ovarian cancer, where early detection is critical, and the adoption of liquid biopsy is slower compared with later-stage monitoring applications.

Tumor heterogeneity and biological variations among patients can affect the sensitivity and accuracy of liquid biopsy testing. Differences in tumor size, growth patterns, and biomarker release levels influence how effectively cancer-derived signals can be detected in blood samples. Researchers are actively working to improve detection sensitivity through improved sequencing depth, advanced molecular assays, and multi-biomarker testing strategies. Limited sensitivity in detecting early-stage cancers restricts the wider use of liquid biopsy as a primary screening method until technological accuracy improves.

Opportunity Analysis - Expansion into Non-Cancer Indications and Population Screening

Liquid biopsy technologies are creating new opportunities beyond traditional oncology diagnostics as researchers explore their use in detecting a wider range of medical conditions. The ability to analyze circulating biomarkers from blood samples provides a minimally invasive approach for monitoring various physiological and pathological changes in the body. This capability is encouraging the development of advanced diagnostic applications that extend beyond tumor detection. As analytical technologies improve, liquid biopsy platforms are expected to support broader clinical uses, enabling healthcare providers to detect diseases earlier and monitor patient health more efficiently through simple blood-based testing methods.

Another important opportunity for the U.S. liquid biopsy market lies in the expansion of large-scale screening approaches designed to identify disease signals before symptoms develop. Advances in molecular diagnostics and sequencing technologies are enabling the development of multi-marker blood tests capable of detecting early biological changes associated with cancer and other conditions. Such innovations can support earlier diagnosis, better treatment planning, and improved patient outcomes. As healthcare systems increasingly prioritize preventive care and early disease detection.

Integration with Immunotherapy Monitoring

Immunotherapy drugs work by stimulating the patient’s immune system to recognize and attack cancer cells. Patient responses to these treatments vary significantly, and monitoring their effectiveness can be challenging. Liquid biopsy offers a non-invasive method to track tumor-derived biomarkers and immune-related molecular changes during treatment. By analyzing circulating tumor DNA and other biomarkers, clinicians can evaluate how well a patient is responding to immunotherapy and adjust treatment strategies accordingly. This approach allows repeated testing without invasive procedures, improving patient comfort and enabling continuous disease monitoring. Increasing adoption of precision oncology in the U.S. is supporting the use of liquid biopsy for therapy monitoring.

Liquid biopsy can help identify resistance mechanisms that develop during immunotherapy treatment. Detecting emerging genetic mutations or molecular changes in real time allows oncologists to modify treatment plans before disease progression occurs. This capability improves personalized treatment management and enhances patient outcomes. Advanced sequencing technologies are enabling more accurate detection of tumor-related genetic changes during treatment. The growing use of molecular profiling in oncology care across U.S. hospitals and diagnostic laboratories is strengthening the role of liquid biopsy in immunotherapy monitoring.

Product Type Insights

Kits and reagents are expected to lead the U.S liquid biopsy market, accounting for approximately 55% of revenue in 2026, driven by their essential consumables used in most liquid biopsy testing workflows. These products play a crucial role in extracting and isolating circulating tumor DNA, circulating tumor cells, and other biomarkers from blood samples. Diagnostic laboratories and hospitals depend heavily on kits and reagents for routine testing, making them a core component of liquid biopsy procedures. For example, QIAGEN N.V. provides the widely used QIAamp circulating nucleic acid kits, which are designed for isolating circulating DNA from plasma and serum samples in liquid biopsy applications.

Services are likely to represent the fastest-growing segment, as healthcare providers increasingly rely on specialized diagnostic laboratories for advanced genomic testing and analysis. Many hospitals and smaller healthcare facilities do not possess the required infrastructure, sequencing platforms, or bioinformatics capabilities needed to perform complex liquid biopsy tests internally. Outsourced testing services allow healthcare providers to access advanced diagnostic technologies without large capital investments in equipment or technical expertise. For example, Guardant Health Inc. offers comprehensive liquid biopsy testing services that analyze circulating tumor DNA to identify actionable mutations in cancer patients. These services enable physicians to obtain molecular insights that help guide targeted therapy decisions and monitor treatment response.

Biomarker Type Insights

Circulating tumor DNA (ctDNA) is projected to lead the market, capturing around 42% of the revenue share in 2026, supported by its effectiveness in identifying tumor-specific genetic mutations and supporting targeted cancer therapy decisions. ctDNA refers to fragments of DNA released into the bloodstream by tumor cells, providing valuable information about the molecular characteristics of cancer without requiring invasive tissue biopsy procedures. The analysis of ctDNA enables clinicians to detect actionable mutations, monitor disease progression, and assess treatment response in real time. For example, F. Hoffmann-La Roche AG developed the cobas EGFR Mutation Test, which detects EGFR mutations from plasma samples in patients with non-small cell lung cancer.

Cell-free DNA (cfDNA) is likely to be the fastest-growing biomarker type in 2026, driven by its broad diagnostic potential and expanding clinical applications. cfDNA consists of small DNA fragments released into the bloodstream from normal and diseased cells, providing valuable genetic information that can be analyzed through advanced sequencing technologies. In oncology diagnostics, cfDNA analysis helps identify tumor-related genetic changes and supports disease monitoring throughout treatment. For example, Illumina Inc. provides advanced sequencing platforms widely used by diagnostic laboratories to analyze circulating DNA in liquid biopsy workflows. These sequencing technologies enable researchers and clinicians to detect subtle genetic variations associated with cancer development and progression.

Indication Type Insights

Lung cancer is estimated to lead the U.S. liquid biopsy market, accounting for approximately 28% of revenue in 2026, due to the high prevalence of the disease and the increasing use of molecular testing to guide targeted therapy. Liquid biopsy plays an important role in lung cancer diagnosis and treatment monitoring, particularly for patients with non-small cell lung cancer. Traditional tissue biopsies can be difficult to obtain in some lung cancer cases because tumors are located in areas that are hard to access surgically. For example, Thermo Fisher Scientific Inc. offers advanced molecular testing solutions that support liquid biopsy analysis for detecting mutations associated with lung cancer. Such diagnostic tools help clinicians identify actionable genetic alterations and guide personalized treatment strategies.

Breast cancer is likely to represent the fastest-growing segment, driven by the increasing adoption of molecular diagnostic tools to monitor disease progression and treatment response. Liquid biopsy testing allows clinicians to detect circulating tumor DNA associated with breast cancer, enabling real-time insights into tumor biology without repeated invasive tissue biopsies. This approach is particularly useful for monitoring metastatic breast cancer, where continuous assessment of genetic changes can help guide treatment adjustments. For example, Exact Sciences Corporation develops advanced molecular diagnostic tests designed to analyze tumor-related genetic signals in blood samples. These diagnostic tools help clinicians better understand disease progression and select appropriate treatment strategies.

The U.S. liquid biopsy market exhibits a moderately fragmented structure, driven by the presence of both established diagnostic companies and emerging biotechnology firms focusing on advanced molecular diagnostics and precision oncology solutions. The market is characterized by continuous innovation in circulating tumor DNA analysis, next-generation sequencing technologies, and blood-based cancer detection platforms. Companies are increasingly investing in research and development to improve the sensitivity and clinical accuracy of liquid biopsy tests for early cancer detection, treatment monitoring, and minimal residual disease analysis.

With key leaders including Guardant Health Inc., F. Hoffmann-La Roche AG, Illumina Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Exact Sciences Corporation, the market is shaped by companies offering a wide range of liquid biopsy technologies, genomic sequencing platforms, and diagnostic assays. These players compete through continuous product innovation, development of highly sensitive blood-based cancer tests, strategic collaborations with pharmaceutical companies, and expansion of genomic testing services.

Key Industry Developments:

• In January 2026, researchers led by Daniel A. Heller at Memorial Sloan Kettering Cancer Center developed an AI-enabled liquid biopsy using carbon nanotube nanosensors capable of detecting and classifying brain tumors from a blood sample. The technology analyzes molecular signals in the blood associated with tumors and their surrounding environment, offering a less invasive approach for diagnosing brain tumors and supporting more precise treatment decisions.
• In February 2026, BillionToOne Inc. expanded its Northstar Select liquid biopsy platform with the launch of two new add on applications designed to enhance molecular cancer diagnostics using blood samples. These new applications build on the existing Northstar Select portfolio to improve genomic analysis capabilities and broaden the clinical utility of liquid biopsy testing, supporting more comprehensive detection of cancer associated genetic alterations.
• In March 2026, Guardant Health Inc. launched the “Shield across America” coast-to-coast mobile screening tour to expand access to its Shield blood-based liquid biopsy test for colorectal cancer across more than 100 communities in the U.S., particularly targeting rural areas with low screening rates to improve early cancer detection through non-invasive blood testing.